Pfizer Reports Q2 Net Loss Due to Asset Write-Downs from Oncology Trial Setbacks

Pfizer reported a Q2 net loss of $248 million due to asset write-downs from underperforming oncology trials, despite a 3% revenue increase.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.